Abstract
BackgroundMavrilimumab is a high-affinity, fully human immunoglobulin G (IgG) monoclonal antibody that selectively binds to the α subunit of GM-CSF receptor (GM-CSFRα). A Phase 2a randomized, double-blind, placebo-controlled, multiple ascending...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have